Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC By Ogkologos - April 15, 2025 423 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUNNIFORECAST study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment September 23, 2019 Higher Risk of Heart Failure Seen in Some Cancers March 26, 2018 Searching for novel connections in cancer metabolism June 19, 2020 Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... January 18, 2022 Load more HOT NEWS Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... What People With Cancer Should Know About Immune Checkpoint Inhibitor Side... Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... Avapritinib Approved to Treat GIST with a Rare Gene Alteration
